Difference between revisions of "Increasing Private Funding (Venture Capital) for Biotech Research and Start-up financing"

From ScenarioThinking
Jump to navigation Jump to search
Line 1: Line 1:
==Description:==
==Description:==
Over the next 5 years, the mobile convergence will develop in three theme
The US Biotech Industry is largely built on Private Venture Capital. Willingness of Private investors to continue sponsoring biotech depends on perspectives of the biotech industry with regards to growth, profitability and scalability. As long as Biotechnology is perceived as a growth industry, venture capital will be available.


Convergence of technology will develop with communication,broadcast and computing
==Enablers:==
• High ROE in Biotech investments
• Attractive Profit margins for biotech drugs
• Controllable investment risk grace to clear and stable legal framework and transparent as well as stable approval rules.
• Reduction of R&D costs thanks to shift of research activities to emerging markets
• Reduction of R&D costs thanks to vast (and steadily increasing) amount of fundamental research available
<br>


Technological capabilities that can be developed on the move are rapidly burring the distinction between mobile phone and PCs.
==Inhibitors:==
• Insecurity regarding the development of legal frameworks
• Drug approval authorities getting more and more strict
• Time periods needed for drug development getting longer
• Other attractive investment topics


Ongoing advances in sophistication,functionality and personalization  will continue to sustain handset renewal
==Paradigms:==
• Is biotech still a hot topic for venture capital investors?


==Enablers:==
==Experts==
o Ubiquity : With forecast billion mobile devices in use by 2007, the 'anytime anywhere' advatages of mobile services are very apparent<br>
See our Financial Research: Link


o Immediacy : Information can be accessed, delivered and acted upon in real time by the user without the start-up time required for a desktop PC<br>
==Timing==
• Tysabri: Suspension of sale per 28.2.05, eventually withdrawn form the market
• Vioxx: Withdrawn from the market per 30. 9.2004
• Veto of US President Bush against Stem Cell Research Bill: May 20, 2005


o Personalization : Mobiles are now personal accessories, capable of holding data and enabling access to information and services which can be tailored to the needs of the individual<br>


o Localization : Recognising where the user is located and matching information or services to that location adds a unique value to mobile services<br>
==Web Resources==
 
See our financial research: Link to our financial research
o Convergence : Thechnological capabilities that can be deployed on the move are rapidly blurring the distinction between mobile phones and PCs. Ongoing advances in sophistication, functionality and personalisation will continue to sustain handset renewal<br>
 
==Inhibitors:==
o Design and potable size(Display,resolution,memory.os)
o Usability(Input/output device)
ㅇCapability(speed),multi task)and interface with another product
==Paradigms:==
People to communication and entertain something to spend a lot of time to use mobile phone anywhere and anytime grows rapidly

Revision as of 12:45, 2 December 2005

Description:

The US Biotech Industry is largely built on Private Venture Capital. Willingness of Private investors to continue sponsoring biotech depends on perspectives of the biotech industry with regards to growth, profitability and scalability. As long as Biotechnology is perceived as a growth industry, venture capital will be available.

Enablers:

• High ROE in Biotech investments • Attractive Profit margins for biotech drugs • Controllable investment risk grace to clear and stable legal framework and transparent as well as stable approval rules. • Reduction of R&D costs thanks to shift of research activities to emerging markets • Reduction of R&D costs thanks to vast (and steadily increasing) amount of fundamental research available

Inhibitors:

• Insecurity regarding the development of legal frameworks • Drug approval authorities getting more and more strict • Time periods needed for drug development getting longer • Other attractive investment topics

Paradigms:

• Is biotech still a hot topic for venture capital investors?

Experts

See our Financial Research: Link

Timing

• Tysabri: Suspension of sale per 28.2.05, eventually withdrawn form the market • Vioxx: Withdrawn from the market per 30. 9.2004 • Veto of US President Bush against Stem Cell Research Bill: May 20, 2005


Web Resources

See our financial research: Link to our financial research

Retrieved from "https://www.scenariothinking.org/index.php?title=Increasing_Private_Funding_(Venture_Capital)_for_Biotech_Research_and_Start-up_financing&oldid=8349"